Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC9204-1177 in Overweight or Obesity
NCT03308721Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2017
- Primary completion
- Jan 2020
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity and Overweight comparing NNC9204-1177 with Placebo (2 arms). Primary endpoint: Number of treatment emergent adverse events. Started Oct 2017; status: completed.
02
Drugs
NN1177
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT03308721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03308721.